Literature DB >> 33525411

Computational Determination of Potential Multiprotein Targeting Natural Compounds for Rational Drug Design Against SARS-COV-2.

Ziyad Tariq Muhseen1,2, Alaa R Hameed3, Halah M H Al-Hasani4, Sajjad Ahmad5, Guanglin Li1,2.   

Abstract

SARS-CoV-2 caused the current COVID-19 pandemic and there is an urgent need to explore effective therapeutics that can inhibit enzymes that are imperative in virus reproduction. To this end, we computationally investigated the MPD3 phytochemical database along with the pool of reported natural antiviral compounds with potential to be used as anti-SARS-CoV-2. The docking results demonstrated glycyrrhizin followed by azadirachtanin, mycophenolic acid, kushenol-w and 6-azauridine, as potential candidates. Glycyrrhizin depicted very stable binding mode to the active pocket of the Mpro (binding energy, -8.7 kcal/mol), PLpro (binding energy, -7.9 kcal/mol), and Nucleocapsid (binding energy, -7.9 kcal/mol) enzymes. This compound showed binding with several key residues that are critical to natural substrate binding and functionality to all the receptors. To test docking prediction, the compound with each receptor was subjected to molecular dynamics simulation to characterize the molecule stability and decipher its possible mechanism of binding. Each complex concludes that the receptor dynamics are stable (Mpro (mean RMSD, 0.93 Å), PLpro (mean RMSD, 0.96 Å), and Nucleocapsid (mean RMSD, 3.48 Å)). Moreover, binding free energy analyses such as MMGB/PBSA and WaterSwap were run over selected trajectory snapshots to affirm intermolecular affinity in the complexes. Glycyrrhizin was rescored to form strong affinity complexes with the virus enzymes: Mpro (MMGBSA, -24.42 kcal/mol and MMPBSA, -10.80 kcal/mol), PLpro (MMGBSA, -48.69 kcal/mol and MMPBSA, -38.17 kcal/mol) and Nucleocapsid (MMGBSA, -30.05 kcal/mol and MMPBSA, -25.95 kcal/mol), were dominated mainly by vigorous van der Waals energy. Further affirmation was achieved by WaterSwap absolute binding free energy that concluded all the complexes in good equilibrium and stability (Mpro (mean, -22.44 kcal/mol), PLpro (mean, -25.46 kcal/mol), and Nucleocapsid (mean, -23.30 kcal/mol)). These promising findings substantially advance our understanding of how natural compounds could be shaped to counter SARS-CoV-2 infection.

Entities:  

Keywords:  COVID-19; MD simulation; SARS-CoV-2; multiprotein inhibiting natural compounds; virtual screening

Mesh:

Substances:

Year:  2021        PMID: 33525411      PMCID: PMC7865386          DOI: 10.3390/molecules26030674

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  69 in total

1.  In-silico identification and evaluation of plant flavonoids as dengue NS2B/NS3 protease inhibitors using molecular docking and simulation approach.

Authors:  Muhammad Tahirul Qamar; Usman Ali Ashfaq; Kishver Tusleem; Arooj Mumtaz; Quratulain Tariq; Alina Goheer; Bilal Ahmed
Journal:  Pak J Pharm Sci       Date:  2017-11       Impact factor: 0.684

2.  Discovery of selective inhibitors for cyclic AMP response element-binding protein: a combined ligand and structure-based resources pipeline.

Authors:  Iqra Muneer; Muhammad T Ul Qamar; Kishver Tusleem; Sadaf Abdul Rauf; Hafiz M J Hussain; Abdul R Siddiqi
Journal:  Anticancer Drugs       Date:  2019-04       Impact factor: 2.248

3.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

4.  Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.

Authors:  Wenhao Dai; Bing Zhang; Xia-Ming Jiang; Haixia Su; Jian Li; Yao Zhao; Xiong Xie; Zhenming Jin; Jingjing Peng; Fengjiang Liu; Chunpu Li; You Li; Fang Bai; Haofeng Wang; Xi Cheng; Xiaobo Cen; Shulei Hu; Xiuna Yang; Jiang Wang; Xiang Liu; Gengfu Xiao; Hualiang Jiang; Zihe Rao; Lei-Ke Zhang; Yechun Xu; Haitao Yang; Hong Liu
Journal:  Science       Date:  2020-04-22       Impact factor: 47.728

5.  COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome.

Authors:  Toshio Hirano; Masaaki Murakami
Journal:  Immunity       Date:  2020-04-22       Impact factor: 31.745

6.  Structure-based drug designing of naphthalene based SARS-CoV PLpro inhibitors for the treatment of COVID-19.

Authors:  Shipra Bhati
Journal:  Heliyon       Date:  2020-11-20

7.  Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.

Authors:  Fumihiro Kato; Shutoku Matsuyama; Miyuki Kawase; Takayuki Hishiki; Hiroshi Katoh; Makoto Takeda
Journal:  Microbiol Immunol       Date:  2020-07-25       Impact factor: 2.962

8.  Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease.

Authors:  Muhammad Usman Mirza; Sarfraz Ahmad; Iskandar Abdullah; Matheus Froeyen
Journal:  Comput Biol Chem       Date:  2020-09-13       Impact factor: 2.877

9.  Comparative Studies of the Dynamics Effects of BAY60-2770 and BAY58-2667 Binding with Human and Bacterial H-NOX Domains.

Authors:  Rana Rehan Khalid; Muhammad Tahir Ul Qamar; Arooma Maryam; Ayesha Ashique; Farooq Anwar; Mohammed H Geesi; Abdul Rauf Siddiqi
Journal:  Molecules       Date:  2018-08-25       Impact factor: 4.411

10.  A Genomic Perspective on the Origin and Emergence of SARS-CoV-2.

Authors:  Yong-Zhen Zhang; Edward C Holmes
Journal:  Cell       Date:  2020-03-26       Impact factor: 41.582

View more
  12 in total

Review 1.  Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature's toolbox of bioactive compounds.

Authors:  Io Antonopoulou; Eleftheria Sapountzaki; Ulrika Rova; Paul Christakopoulos
Journal:  Comput Struct Biotechnol J       Date:  2022-03-14       Impact factor: 7.271

Review 2.  Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.

Authors:  Kaifu Gao; Rui Wang; Jiahui Chen; Limei Cheng; Jaclyn Frishcosy; Yuta Huzumi; Yuchi Qiu; Tom Schluckbier; Xiaoqi Wei; Guo-Wei Wei
Journal:  Chem Rev       Date:  2022-05-20       Impact factor: 72.087

3.  Structural Elucidation of Rift Valley Fever Virus L Protein towards the Discovery of Its Potential Inhibitors.

Authors:  Mubarak A Alamri; Muhammad Usman Mirza; Muhammad Muzammal Adeel; Usman Ali Ashfaq; Muhammad Tahir Ul Qamar; Farah Shahid; Sajjad Ahmad; Eid A Alatawi; Ghadah M Albalawi; Khaled S Allemailem; Ahmad Almatroudi
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-25

Review 4.  Virtual screening of substances used in the treatment of SARS-CoV-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses.

Authors:  Paul Andrei Negru; Denisa Claudia Miculas; Tapan Behl; Alexa Florina Bungau; Ruxandra-Cristina Marin; Simona Gabriela Bungau
Journal:  Biomed Pharmacother       Date:  2022-07-18       Impact factor: 7.419

5.  A computational study of cooperative binding to multiple SARS-CoV-2 proteins.

Authors:  Jianing Li; Kyle T McKay; Jacob M Remington; Severin T Schneebeli
Journal:  Sci Rep       Date:  2021-08-11       Impact factor: 4.996

Review 6.  Ayurveda Rasayana as antivirals and immunomodulators: potential applications in COVID-19.

Authors:  Rajeshwari Singh; Sumeet Goel; Pascale Bourgeade; Lotfi Aleya; Devesh Tewari
Journal:  Environ Sci Pollut Res Int       Date:  2021-09-07       Impact factor: 5.190

Review 7.  Comparing the Nucleocapsid Proteins of Human Coronaviruses: Structure, Immunoregulation, Vaccine, and Targeted Drug.

Authors:  Bo Zhang; Junjie Tian; Qintao Zhang; Yan Xie; Kejia Wang; Shuyi Qiu; Keyu Lu; Yang Liu
Journal:  Front Mol Biosci       Date:  2022-04-29

8.  Mechanistic insights from the review and evaluation of ayurvedic herbal medicines for the prevention and management of COVID-19 patients.

Authors:  Prasanta Kumar Sarkar; Chitrangada Das Mukhopadhyay
Journal:  J Herb Med       Date:  2022-02-18       Impact factor: 3.032

9.  Computational Approaches: Drug Discovery and Design in Medicinal Chemistry and Bioinformatics.

Authors:  Marco Tutone; Anna Maria Almerico
Journal:  Molecules       Date:  2021-12-11       Impact factor: 4.411

Review 10.  A review of natural products, their effects on SARS-CoV-2 and their utility as lead compounds in the discovery of drugs for the treatment of COVID-19.

Authors:  Robert L Chapman; Shridhar V Andurkar
Journal:  Med Chem Res       Date:  2021-12-02       Impact factor: 1.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.